4/21/2021

speaker
Gary
Conference Specialist

Good afternoon, and welcome to Synthetic Biologics 2020 Year-End Investor Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw your question, please press star, then two. Please note, this event is being recorded. At this time, I would like to turn the call over to Vincent Perrone, Director of Corporate Communication at Synthetic Biologics. Please go ahead.

speaker
Vincent Perrone
Director of Corporate Communication

Thanks, Gary, and good afternoon, everyone. Welcome to Synthetic Biologics 2020 Year-End Investor Conference Call. Today, I'm joined remotely by Stephen Shawcross, Chief Executive and Financial Officer, Dr. Michael Calico, Senior Vice President, Research and Development, and Dr. Vince Wager, head of product and corporate development. Synthetic Biologics issued a press release this afternoon, which provided operational highlights and reported our financial results for the year ending December 31st, 2020. The release can be found on the investor relations section of our website. During our call today, we'll provide an operational update on our GI and microbiome-focused clinical programs and summarize our financial results. We'll take questions after prepared remarks. In addition to the phone line, this call will be streamed live via webcast and will be archived on our website at www.syntheticbiologics.com for 90 days. During this call, we will be making forward-looking statements regarding Synthetic Biologics' current expectations and projections about future events. Generally, the forward-looking statements can be identified by terminology such as may, should, expects, anticipates, intends, plans, believes, estimates, and similar expressions. These statements are based upon current beliefs, expectations, and assumptions and are subject to a number of risks and uncertainties, including those set forth in synthetic biologics violence with the SEC, many of which are difficult to predict. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. The information on this call is provided only as of the date of this call, and synthetic biologics undertakes no obligation to update any forward-looking statements contained on this conference call on account of new information, future events, or otherwise, except as required by law. With that, I'd like to turn the call over to Steve. Steve?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Thanks, Vincent. Good afternoon, everyone, and thank you for joining our 2020 year-end investor conference call. I hope everyone is staying safe and healthy as we continue to navigate the global health crisis sparked by the COVID-19 pandemic. It was a busy year, and the start of the new year for the CIN team. I'm very excited to be with you this afternoon to share our operational highlights and financial results. I'd like to start our call by saying that we are more encouraged than ever by the outlook for our business. We've made important progress this year by advancing and demonstrating the significant value of our pipeline of GI and microbiome folks clinical programs. And as we look ahead into 2021 and 2022, there are more reasons than ever to be excited about our company's future prospects. Before I give you an update on our two lead clinical programs, I'd like to provide a brief recap of several operational milestones which have unquestionably allowed us to strengthen our balance sheet and position our company for what I believe will be significant long-term growth, as well as the delivery of multiple short and long-term clinical milestones. Starting in January, favorable market conditions triggered the exercise or the cash exercise of approximately 65 percent of the warrants associated with our 2018 public financing and allowed us to efficiently utilize our at-the-market facility. In addition, The conversion of all of our outstanding shares of Series A and Series B convertible preferred stock into common stock have not only further helped streamline our capital structure and balance sheet, but allowed us to position the company to meet the conditions to fully regain NYSE listing compliance. As a result of these activities, we're pleased to announce that our current cash balance is approximately $72.6 million. the strongest cash position in the company's history. Our strength in financial position now provides us with the runway to continue our operations well into 2023. Importantly, we now have the financial foundation to fully fund our Phase 1b-2a clinical trial of SIN4 and planned Phase 1 and Phase 2 clinical studies of SIN20. In addition, we are now positioned to evaluate and potentially acquire new technologies and or assets intended to enhance our development pipeline, which we believe may benefit from our incredibly experienced team. As we anticipate clinical trials returning to normal, our recently strengthened financial position will allow us to conduct multiple clinical studies during the next several years advancing our portfolio of GI-focused clinical programs through proof of concept. As we think about the remainder of 2021 and moving into 2022, we are excited about several potential catalysts and clinical milestones that can create additional significant value for our shareholders. Specifically, for SYN4, our therapy and development to prevent acute graft-versus-host disease, or AGVHD, We are excited to announce that Washington University has begun screening patients for enrollment of the first cohort in the Phase 1b2a clinical trial in L-Geneic Metabiotic Cell Transplant, or HCT, recipients. We expect to begin dosing patients in this cohort before the end of the month and if enrollment proceeds as planned. we will be positioned to announce up to three interim data readouts during the next 12 to 18 months, with the first one anticipated before the end of the year, pandemic conditions permitting. For SYN20, our intestinal alpha-mphosphatase program, a phase one single ascending dose study, or SAD study, is expected to begin during the second quarter. A top line readout for this clinical trial is expected during the third quarter of 2021 and a second phase one multiple ascending dose study or MAD study of CIN20 is expected to begin in Q3 with top line data expected in Q1 of next year. Both phase one trials are designed to support the development of CIN20 in multiple clinical indications. Following what we believe will be a successful Phase I program, we are preparing a Phase II clinical study in celiac patients, as well as clinical programs for other potential indications that could begin as soon as early 2022. We believe CIN4 in development to prevent AGVHD and CIN20, a recombinant intestinal alkaline phosphatase program, address very sizable and underserved markets, and have the potential to be foundational, long-term drivers of value for our company and our shareholders. With that backdrop, I'd like to provide an update on our clinical development activities, beginning with our SYN4 or ribaximase program. SYN4 is our first-in-class therapeutic intervention designed to protect the gut microbiome from antibiotic-mediated dysbiosis. We believe protection of the gut microbiome may play a pivotal role in improving health outcomes for patients administered long courses of intravenous beta-lactam antibiotics as part of their treatment plan for bone marrow and solid organ transplantations. Elgin egg HCT recipients routinely receive long courses of IV beta-lactam antibiotics to treat neutropenic fever, which occurs in 80 to 90 percent of the patients. Microbiome damage from IV beta-lactam antibiotics is associated with AGVHD, VI recolonization, bacteremia, and C. difficile infection. AGVHD occurs in 30 to 60% of L-genetic HCC recipients and is a leading cause of graft failure and mortality. Prevention of AGVHD is absolutely critical in this patient population. since first-line AGVHD steroid therapies fail in more than 50% of the patients, resulting in two-year survival rates of around 20%. The use of SYN4 in L-genetic HCT patients is well supported by our existing clinical data, and SYN4's potential to preserve the intestinal microbiome in L-genetic HCT recipients could provide remarkable benefits to patients, providers, and payers. Estimates of in-hospital costs for L-genetic HCT recipients in the U.S. range from $180,000 to more than $300,000. All-cause inpatient and outpatient costs are estimated to be greater than $600,000 per patient when measured up to 12 months after hospital admission. At least one U.S. study found that L-genetic HCT recipients who developed AGVHD had a three times higher in-hospital mortality rate and almost two-fold increase in higher median hospital costs than patients who did not develop AGVHD. If SYNFORM could reduce AGVHD incidence by 30%, it may provide significant improvements in patient outcomes including prevention of an average of 11 deaths and a reduction of $4.3 million in hospital treatment costs per 1,000 patients. In 2018, there were approximately 29,000 L-genetic ACT procedures conducted in the US and Europe, and an additional 13,000 procedures conducted in Japan and China. While these are comparatively small patient numbers, the substantial potential benefits Sinform may provide in this patient population could allow for premium pricing and significant market value. Conservatively, our modeling suggests a revenue opportunity in the U.S. and European markets of more than $800 million in the first five years of sales when considering pricing of $1,000 a day for 14 days of treatment. if we were able to expand the opportunity for SIN4 use in solid organ transplant recipients, the market opportunity could be four times larger. It is worth noting that developing SIN4 for use in this specific patient population may also provide an opportunity to seek orphan drug designation, which may further facilitate Phase III clinical developments. Last year, we outlined our plan to move this program forward in collaboration with our clinical development partner, the Washington University School of Medicine in St. Louis, in the form of a Phase 1b-2a clinical trial of SYN4 and L-genetic HCT recipients. The goal of this study is to evaluate the safety, tolerability, and pharmacokinetics of SYN4 administered to as many as 36 adult L-genetic HCT recipients who receive an who receive a beta-lactam antibiotic to treat fever. Participants will be enrolled in three sequential cohorts that will be administered a different IV beta-lactam antibiotic. Eight participants in each cohort will receive SYN4 and four will receive placebo. Patients enrolled in the first antibiotic cohort will receive the antibiotic meropenem, which is not degraded by SYN4, in order to determine whether SYN4 is systemically absorbed in this patient population. Pharmacokinetic data from our previously completed phase one and phase two clinical trials provided supporting evidence that SYN4 should not affect the IV antibiotic in the bloodstream. If we see that SYN4 is not systemically absorbed in this first cohort, will consider applying for orphan drug designation and begin to prepare for our phase three program as the remainder of this clinical trial completes. At this time, Washington University is currently screening patients for enrollment in this first cohort, and dosing of the first patient is expected to take place this month. If enrollment proceeds as planned, a top line data readout for the first cohort may be available before the end of the year. Next, I'd like to turn the call over to my colleague, Dr. Michael Calico, who will provide an update on our CIN20 intestinal alkaline phosphatase, or IAP program, which is currently being developed as a treatment for celiac disease, as well as other potential GI and systemic inflammatory and age-related disorders. Mike?

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

Thanks, Steve. I welcome this opportunity to discuss the CIN20 program and to outline the anticipated clinical program in our selected indications. We're about to reach an important milestone with the first clinical trial scheduled to begin next month. CIN20 is a high-specific activity form of intestinal alkaline phosphatase, which I'll refer to as IAP. produced recombinantly in show cells and delivered orally. It's formulated to be protected in the stomach and released in the upper small intestine. SYN20 is resistant to digestion and is anticipated to remain in the GI tract and eventually emerge in the stool in active form. IAP is an endogenous enzyme produced by the cells that line the small intestine, and it has multiple functions. Three in particular. First, it removes the phosphate from inflammatory mediators such as endotoxin to diminish local inflammation in the GI tract. Second, IAP acts directly on the cells that line the GI tract to improve barrier function and diminish so-called leaky gut. And third, IAP serves to maintain a healthy microbiome. The combination of these three functions suggest that, in addition to its role in diminishing GI inflammation, IAP may also diminish the low-grade systemic inflammation that has been associated with metabolic diseases and with aging. The therapeutic potential of IAP supplementation has been verified in many animal studies. Oral administration of IAP to rodents that have been efficacious in virtually every model of colitis, as well as models of metabolic syndrome and liver disease. Interestingly, a recent publication from our collaborator, Dr. Richard Hoden at Massachusetts General Hospital, showed that long-term supplementation of IAP in mice diminished the inflammatory and metabolic changes that occur with normal aging and prolonged the mouse lifespan. Why then haven't other companies developed oral IAP products? The answer would seem to be that it's remarkably difficult to manufacture. Most of the studies in the literature have been performed with IAP derived from calf intestines. Calf intestinal IAP cost up to $10,000 per gram, which is prohibitive for an oral therapeutic. And published reports of various recombinant platforms have described very poor yields. Again, insufficient for an oral therapeutic. At Synthetic Biologics, we've overcome this hurdle. Our unique advantage is that we've been able to generate a high-yield production cell line that, at commercial scale, is anticipated to enable cost-effective manufacturing. We've shown that our recombinant IAP that is FIN20, is biologically equivalent to calf-derived IAP, and it was well-tolerated in mouse and dog toxicology studies. The dose is up to 50-fold above the anticipated clinical dose. Last June, we filed an IND application that received a study-may-proceed approval from the FDA for a first-in-human phase one single ascending dose clinical study to evaluate SYN20 safety, tolerability, and bio-distribution in healthy volunteers. I'm really excited to say that this first clinical study is scheduled to begin next month. Four cohorts will be run sequentially, and top-line data are anticipated in the third quarter of this year. The single ascending dose study will be followed by a multiple ascending dose study, again to assess safety, tolerability, and biodistribution, but in this case with twice daily dosing for 10 days. We're aiming to initiate the study in the third quarter of this year with top line data anticipated by the first quarter of next year. Importantly, both of these phase one studies are designed to provide support for subsequent clinical trials in multiple indications. We've previously discussed three potential indications for early CIN20 evaluation. Radiation enteropathy, gluten enteropathy or celiac disease, and non-alcoholic fatty liver disease. We've now prioritized these indications and devised a clinical development plan for the ensuing two to three years. Our initial indication for CIN20 clinical development will be celiac disease. an autoimmune disease triggered in genetically predisposed individuals by ingestion of gluten proteins from wheat as well as other grains. Celiac disease prevalence is approximately 1% of the U.S. population and includes children and adults. The clinical manifestations include both gastrointestinal and systemic symptoms. While the disease presentation and course vary from patient to patient, The underlying causes are the same. Specifically, gluten-derived peptides open the gut barrier, leak into the intestinal wall, stimulate an inflammatory response, and then cause an autoimmune reaction to human proteins, most notably, tissue transglutaminase. The disease is unique among autoimmune disorders in that the trigger, that is gluten, is known and its withdrawal can, in most cases, mitigate the symptoms. Celiac disease has a very significant unmet medical need. There are no pharmaceutical treatments. Patients are condemned to a lifelong, highly restrictive gluten-free diet. Even then, some patients fail to respond to the diet. The disease can be very severe and, in rare cases, can lead to early death from lymphoma. From a mechanistic perspective, we believe CIN20 is well-suited to improve clinical outcomes when combined with diet. First, by bolstering the gut barrier, CIN20 may block the initial step of gluten entry into the intestinal wall. Second, through its anti-inflammatory activities, CIN20 may serve to attenuate the immune response to the gluten peptides. And finally, patients with active celiac disease have been shown to have reduced levels of their own endogenous IAP, presumably because the disease damages the intestinal villi that normally produce IAP. Thus, SYN20 in celiac patients would potentially supplement and correct their low endogenous IAP level. The first proposed clinical evaluation of SYN20 in celiac patients will be a six-week phase 1B-2A gluten challenge study in patients who are well-controlled on a gluten-free diet. It's anticipated that the phase 1B-2A study will be followed by a 12-week phase 2B study in patients who are poorly controlled on a gluten-free diet. Clinical endpoints for both studies will include patient-reported outcomes, laboratory data, and endoscopic biopsies. Assuming successful completion of the Phase 1 studies in healthy volunteers, the Phase 1b-2a study in celiac patients is tentatively scheduled to commence in the second half of next year. It's anticipated that these two studies will provide information with safety potential efficacy, and therapeutic dose to support subsequent pivotal studies. I'm also very pleased to announce that we have engaged, as a consultant, Dr. Alessio Fasano at Harvard University in Massachusetts General Hospital. Dr. Fasano is the Division Chief of Pediatric Gastroenterology and Nutrition and the Director of the Center for Celiac Research and Treatment. More to the point, Dr. Fasano is a world-leading key opinion leader in the field of celiac disease who can guide us through the clinical analyses. Finally, I would like to finish by reemphasizing that CIN20 has the potential to treat both gastrointestinal and systemic diseases. Accordingly, we're currently drafting a clinical plan to evaluate CIN20 for the treatment of non-alcoholic fatty liver disease. The utility of CIN20 for this indication is well supported by efficacy studies in multiple animal models of metabolic and liver disease. Briefly, we anticipate clinical entry as a phase 1B placebo-controlled double-blind study in patients with modest elevations of serum liver enzymes. The study will address safety and tolerability and follow the liver enzymes as well as relevant metabolic parameters. To assist with the clinical design, I'm very pleased to announce that we've engaged, as a consultant, Dr. Rohit Lumbaugh at UC San Diego. Dr. Lumbaugh is the director of the NAFLD, non-alcoholic fatty liver disease, research center, and a world leading KOL in the field of non-alcoholic fatty liver disease. I'll provide more on this indication as the plan materializes. In short, we are excited to see the CIN20 program advance into the clinic. Thanks for your attention, and I'll turn it back to Steve.

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Thanks, Mike. Our CIN20 platform technology has a remarkable opportunity to help address a considerable unmet need for innovative new therapies targeting GI disorders stemming from immune and inflammatory responses, including celiac disease. Currently, there are no FDA-approved therapies to treat celiac disease, and disease management predominantly relies on lifestyle modifications and adherence to a strict gluten-free diet. Across the six major markets, the total prevalent cases of celiac disease are expected to increase from 5.8 million cases in 2013 to an expected 8.1 million cases in 2023, representing an annual growth rate of approximately 4%. During the same period, Prevalent cases in the U.S. are expected to increase from 2.8 million in 2013 to an expected 4.3 million in 2023, representing a significant market opportunity. Non-alcoholic fatty liver disease is also an indication with high unmet need. It is estimated that the worldwide prevalence of non-alcoholic fatty liver disease is anywhere from 6 to 33%. In the U.S., non-alcoholic fatty liver disease is highly prevalent with an estimated prevalence of approximately 30% in the general population. Non-alcoholic fatty liver disease is also strongly associated with metabolic syndrome, and like celiac disease, no approved pharmaceutical therapies are available to treat this illness, and disease management is dependent on lifestyle modifications. I hope we've conveyed our excitement for this versatile program and its potential to become a platform therapeutic for our company. We believe CIN20 will play a major role in delivering long-term value to our shareholders while targeting large, underserved markets, including celiac disease. With that backdrop, I'll review our financial results for the year ended December 31, 2020. Throughout 2020, we operated very efficiently. We remained focused on prudent cash management and continued to identify areas to further reduce nonessential operating expenses. We ended the year with approximately $6 million in cash and cash equivalents. However, due to favorable market conditions, which triggered the cash exercise of approximately 65% of the warrants associated with our 2018 public financing and the efficient utilization of our at-the-market facility, our current cash position is approximately $72.6 million. Now I'll turn to the year-end financial results. General and administrative expenses increased to $5 million for the year ended December 31, 2020 from $4.6 million for the year ended December 31, 2019. This increase of 8.7% is due to increased legal costs related to business development, patent execution, employee contract matters, vacation expense, insurance costs, and registration fees. The charge related to stock-based compensation expense was $300,000 for the year ended December 31, 2020, compared to $300,000 for the year ended December 31, 2019. Research and development expenses decreased to $5.1 million for the year ended December 31, 2020, from $11.1 million for the year ended December 31, 2019. This decrease of 54.1% is primarily due to a reduction in preclinical and manufacturing activity of the SIN20 IAP program and the result of the response to the global COVID-19 pandemic by our clinical development partners, which led to the postponement of the Phase 1B two-way clinical trial of SIN4 in L-genetic HCT recipients, the SIN10 clinical trial, and to a lesser extent, the discontinuation of the Phase 2B investigator-sponsored clinical trial of SIN10. Research and development expense also included a charge related to non-cashed Stock-based compensation expense of $66,000 for the year ended December 31, 2020 compared to $75,000 for the year ended December 31, 2019. Total other income was $44,000 for the year ended December 31, 2020 compared to other income of $283,000 for the year ended December 31, 2019. Total other income for the year ended December 31, 2020 and 2019 is primarily comprised of interest income from investments. I hope we've conveyed in our remarks the embarking on a transformative and exciting direction that we're taking our company. We believe our newly found financial strength and long-term outlook will allow us to unlock and further showcase the value of our clinical assets and generate long-term and value for our shareholders. Looking ahead to the remainder of 2021 and into 2022, upcoming significant major announcements and potential catalysts include for SYN4, our program in the development to prevent acute graft-versus-host disease, we anticipate dosing the first patient in the Phase 1b2a clinical trial this month. And if enrollment proceeds as planned, A top-line data readout for this first cohort is expected before the end of the year. For SIN20, our therapeutic intended to treat celiac disease, a first Phase I single ascending dose study is expected to commence next month, and a top-line data readout is expected during Q3 of this year. A second Phase I multiple ascending dose study is expected to start next in Q3, and a top-line data readout from this clinical study is expected during the first quarter of 2022. Following the completion of our Phase I studies, we're preparing for our Phase II proof-of-concept clinical studies in celiac patients while also planning for clinical studies to evaluate CIN20 for use in other potential indications that could also begin as soon as early 2022. We look forward to continuing to update you on our progress in the weeks and months ahead. So now I'll turn the call back over to Vincent.

speaker
Vincent Perrone
Director of Corporate Communication

Thanks, Steve. Gary, we'd like to open the phone line to questions. Can you please describe the procedure to ask questions for our listeners?

speaker
Gary
Conference Specialist

To ask a question, you may press star then 1 on your telephone keypad. If you are using a speakerphone, please pick up your handset before pressing the keys. To withdraw your question, please press star, then two. At this time, we will pause momentarily to assemble our roster. Our first question is from Jim Malloy with Alliance Global Partners. Please go ahead.

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

Hey, guys. Good afternoon. Thank you for taking my questions. And certainly a lot going on, a nice change from some previous calls that We've got some good cash in and it looks like an exciting 2021 is setting up here. I'd love to go through some of the NAFL. I think right at the end you're talking about the Phase 1s for the NAFL. And I was wondering on the Phase 1, is the Phase 1 that you're currently running for Celiac, will that sort of cover the NAFL because you're on a separate Phase 1 for that? And what's kind of the timing on that?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Okay, so thanks for the questions, Jim. I'm going to let Mike take that question and walk you through the Phase I programs. And as you'll see from his discussion, the data that we gather from the Phase I studies will allow us to advance the program in multiple indications for Phase II. But I'll let Mike walk you through that again.

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

Okay, thanks. So, the initial phase one studies will be a single ascending dose study and a multiple ascending dose study. Those should both, the single ascending dose study will be completed this year. The multiple ascending dose study will start this year and be completed early next year. Both of those are in normal healthy volunteers. They're designed to demonstrate safety, tolerability, and biodistribution. we would like to show that SYN20 stays in the GI tract, which it should, and not move into the systemic circulation. Once those safety studies are completed, then we go into a phase 1B, 2A study in celiac disease. That's the challenge study, and that should start in the middle of next year, and that will be followed by a phase 2B study in celiac patients shortly thereafter. Now, as a separate indication, there's non-alcoholic fatty liver disease. Okay, that'll start as a phase 1B study in patients with mild elevations of liver enzymes. And we expect that during that study, or we hope to see the liver enzymes and we'll also be following other metabolic parameters for target validation in those patients. Now, those two patient studies, celiac and non-alcoholic fatty liver disease, are independent. They are both supported by the phase one SAD and MAD studies in normal healthy volunteers. But the patient studies are independent. At the moment, we plan to start the celiac study very shortly after the MAD study in normal healthy volunteers is finished. And then somewhere along the way, we would move into non-alcoholic fatty liver disease. And the timing for that is not yet determined. but it can potentially be run in parallel with celiac. It is not dependent upon celiac. Does that clarify things? That does very much clarify things. Thank you very much. You get a lot of trials running, sort of starting up here, but thank you for laying that out. Yes, pretty cool. Yes, indeed. On what you may anticipate for spend, For 2021 with these various trials, you guys burned through about 10.1, 10.2 million in 2020, down from obviously, again, down from 15.6 last 2019. Do we get back to the 15 levels with the cash on hand and trials ramping up, or do we stay sort of somewhere between 10 and 15? Any guidance on that?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Yeah, I would expect our fixed burn to stay in the $400,000 to $500,000 a month that might start to increase a little bit more next year. The phase one study that will be conducted starting this next month, the SAD study, it's probably around a million dollar study. The second one, the MAD study, you could probably think about it in terms of about a million and a half dollars The ongoing trial that is about to get underway with WashU, as we previously disclosed, that's about a $3.6 million trial. About $700,000 has already been spent on that, so there's just under $3 million or so that would be spread over the next 12 to 18 months. The Phase II programs, we haven't, you know, finalized our costs on that yet. So, when we have a little bit more clarity on that, we'll share that. Does that help you out?

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

Very helpful. Thank you. And then, this is my last question. You have a couple other, you know, a couple of programs obviously didn't work out and, you know, the nature of drug development, but CIN10 and sort of the thoughts on the C. diff program. what should we anticipate you guys might do with these compounds? Is it something that is in interest from potential partners, or are these just pretty much going to be shelved for the future?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

So the SIN 10 program, we've discontinued our license with Cedars-Sinai. It was a mutual termination. So we are not spending any more money on that program, and we've moved on from it. I'll let Vince Wager talk about our long-term strategy as it relates to CIN4 or ribaximase and where we're beginning and ultimately how we could get to a broader C. diff indication. Vince, you want to take that?

speaker
Dr. Vince Wager
Head of Product and Corporate Development

Thanks, Dave, and Jimmy. The C. diff compounds and the bone marrow transplant, the LOHCT compound, are one and the same, exactly the same product. are pursuing the bone marrow indication because it enables us to advance the product more effectively in a smaller number of patients and smaller clinical trials and ideally with a greater number of endpoints that we can evaluate to help move that program forward. The mechanism is exactly the same for both indications, the bone marrow transplant and the C. diff, and in fact, preventing C. diff is an anticipated outcome in bone marrow transplant patients in addition to reducing GVHD. So this, one of the ways to think about the overall development plan is that we start with the bone marrow transplant patients looking at GVHD, looking at VRE colonization, and also looking at C. difficile and other opportunistic infections. And that data can be leveraged to move into broader populations. So Steve had referenced the solid organ transplant population. We know that they have issues with opportunistic infections in those immunosuppressed patients. And so that's an indication where if we expanded, we'd be more focused on the opportunistic infections like C. diff. And then ultimately, using the data that's accumulated as we move through these increasing indications to get back to the broader use in C. diff. which, as we've explained before, required a massive phase three trial that was beyond us at the time, and so we're pursuing this more focused approach to get the product forward and generate that data. Excellent.

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

Thank you for taking the question.

speaker
Gary
Conference Specialist

The next question is from Jason McCarthy with Maxim Group. Please go ahead.

speaker
Michael Kunowich
Analyst, Maxim Group

Hey, this is Michael Kunowich on the line for Jason. Thanks for taking my question. Congratulations on the progress. It seems like, you know, things are really moving forward now. Thanks. So I'd like to ask regarding the trial design for SYN4, if you could give a bit more on that, like the overall timeline for the study and which antibiotics from the three cohorts and which of the cohorts is the one you're expecting to read out by year end?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Why don't you go ahead, Vince, and take that one as well.

speaker
Dr. Vince Wager
Head of Product and Corporate Development

No problem. So it's the three-cohort study, and each cohort uses a different antibiotic. And the way that they're staged is to minimize risk to the patients based on the potential effects of Sino4. So to quickly recap, Sino4 degrades penicillin and cephalosporin antibiotics, but not carbapenem antibiotics. So what we want to do is start with a carbapenem antibiotic in our first cohort and measure the potential for absorption of SinoA4 in what would be considered the cohort of lowest risk if there was any absorption, because our product doesn't degrade carbapenems, even if it got in, and we don't believe it will, even if any got in, it's not likely to affect the antibiotic because it's a carbapenem. If that cohort... proves to give us the results that we need if we have a successful completion of that cohort, that's the one that we'll initially read out. And the data we'll get from that will be safety and tolerability data of SinoA4 in the target population. We'll also get a read on whether or not SinoA4 is absorbed into the circulation of patients with impaired barrier function. And those are two key questions that the FDA had for the program in general. So with that data in hand, we will be able to proceed to the next cohort, which will be piperacillin-tazobactam, which is a cohort where piperacillin can be degraded by ZnO4 if it was present in the circulation, but tazobactam stops it from doing that. So these patients have a minder. They have a bodyguard for their antibiotic that would, if our product got absorbed, it would prevent it from degrading. So that's the next risk level. And that's, again, a cohort that would read out subsequent to the first one and give us another set of PK data, another set of antibiotic data, and safety data. And the final cohort is cefepime. That's a cephalosporin antibiotic. and that antibiotic is exposed. It could be degraded by our product, and it has also got nothing to protect it. So it is a product that's the final cohort that we would run because that's the one where if our drug got into the circulation, it would be the highest risk of degrading the antibiotic.

speaker
Michael Kunowich
Analyst, Maxim Group

All right. Thank you. And then I'd actually like to touch on the – M&A side of things. You mentioned that business development is a potential and wouldn't be surprising given that you have a fairly stable cash balance at this point. So what sort of compounds would you be looking for? It seems like you guys have expertise in GI microbiome health as well as GI delivery of drugs. So could you help narrow down which disease areas or which type of drugs you might target?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

So I think it's best that we kind of hold our cards a little tight at the moment. I can tell you this. We've been evaluating many opportunities, and some are a little bit further along than others in diligence. And I'll just say that when we're ready to talk about those details, we'll get that out and disseminate it accordingly. But, you know, we just prefer to keep our cards close at this point.

speaker
Michael Kunowich
Analyst, Maxim Group

All right. And then I have one more I'd just like to touch real quick on some of the existing safety data out there for IAP. I mean, obviously, you don't have anything for SIN 20 quite yet, but IAP has been out there. So, you know, patients with radiation enteropathy and severe celiac may be willing to take on some safety risk or some adverse events, but diseases like well-controlled celiac and NAFLD, which is largely asymptomatic, may be less willing to take those risks. So how does the safety look like for IAP in general?

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Mike, you want to take that?

speaker
Dr. Michael Calico
Senior Vice President, Research and Development

The IAP, as I said, is an endogenous enzyme. It's in your intestines all the time, although we're using a bovine version of it because it's got a higher specific activity. The safety profile for IAP is very good. I would be even more effusive, but I don't think that's necessary at this point. Our, for our SYN20, we saw virtually no adverse events in canine and mouse studies that were six weeks long, at doses up to 50-fold the anticipated clinical dose. Now, other companies have developed both bovine and human IAP products, most notably though for intravenous use. And in the safety studies, again, there was pretty much a fairly remarkable profile. I really don't want to speak completely for other companies because I'm not privy to their data, but for the most part, intravenous delivery of human IAP in patients at doses that increase the alkaline phosphatase level, geez, I believe about 500-fold. about background, was well-tolerated. And there's been one oral study with bovine IAP, again, very well-tolerated. That was in ulcerative colitis patients. And let's see. I think that's probably about it. you can consider the safety profile that we anticipate to be quite good. We anticipate a very reasonable risk-benefit ratio, even for diseases that are not fatal. And I should also finally add that celiac disease, yes, there are patients who are well controlled on a gluten-free diet. But that's a really unpleasant diet. There are a large percentage of patients who are not well-controlled on a gluten-free diet, and some will have refractory disease. So I don't think we'll have trouble finding, or I don't anticipate that we'll have trouble finding a patient population as a home for 10, 20. And I think you know that among patients with non-alcoholic fatty liver disease, maybe 20% of them we'll go on to get NASH, which is associated with fibrosis, cirrhosis, and occasionally a paracellular carcinoma. So, again, I don't think we'll find difficulty finding a patient population for CIN20. Does that answer your question?

speaker
Michael Kunowich
Analyst, Maxim Group

Yeah, yeah, great answer. Thank you very much.

speaker
Gary
Conference Specialist

This concludes our question and answer session. I would like to turn the conference back over to Steve Shawcross for any closing remarks.

speaker
Stephen Shawcross
Chief Executive Officer & Financial Officer

Thanks again, Gary. So before we end the call, I'd just like to make a few final comments about our company. First, I'm incredibly proud of our talented team who have just worked countless hours to get us where we're at today. The effort taken to advance our programs just could not have happened without their dedication and persistent drive to help a patient population that just continues to be underserved. Second, we're in the strongest financial position in the company's history. And because of this, we're now very, very well positioned to not only fund our clinical programs for the next two years, but to deliver on multiple clinical milestones over the next 12 to 24 months. So the value of these programs that we have under development can be further supported and potentially the value potentially fully realized by the markets. And we also have this great, great opportunity finally to go out and acquire or license new technologies to further expand our product portfolio and add additional shareholder value. So in closing, I'd like to thank our long-term shareholders for their ongoing support and also just welcome any new shareholders that have discovered us and are equally excited to be a part of our great company. I promise you that 2021 will be an exciting year and we look forward to just keeping you informed and updated on our progress. Have a good weekend and we look forward to talking to you next time. Thank you.

speaker
Gary
Conference Specialist

The conference is now concluded. Thank you for attending today's presentation. You may now disconnect.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-